Precision Biosciences Inc. (DTIL)
Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates
Precision BioSciences (DTIL) came out with a quarterly loss of $3.20 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $3.35 per share a year ago.
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel
Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and has secured strategic partnerships for azer-cel's development in cancer and autoimmune disorders. TG Therapeutics' BRIUMVI achieved significant sales growth in 2024, supporting positive cash flow and funding for future developments, including azer-cel for autoimmune disorders. DTIL is rated a speculative "Buy" due to its undervaluation, promising pipeline, and strategic partnerships, while TGTX is rated "Hold" due to its full valuation.
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
On Wednesday, Precision BioSciences, Inc. DTIL revealed initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial.
Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst
On Thursday, Precision BioSciences Inc.'s DTIL partner iECURE reported clinical efficacy and safety data in the first patient dosed with ECUR-506 in the Phase 1/2 OTC-HOPE study.
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates
Precision BioSciences (DTIL) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $3 per share a year ago.
Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 277.6% in Precision BioSciences (DTIL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock
Precision BioSciences (DTIL) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade
The consensus price target hints at a 307.9% upside potential for Precision BioSciences (DTIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates
Precision BioSciences (DTIL) came out with quarterly earnings of $3.46 per share, beating the Zacks Consensus Estimate of a loss of $0.77 per share. This compares to loss of $3 per share a year ago.
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
The mean of analysts' price targets for Precision BioSciences (DTIL) points to a 200.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Q2 2024 Earnings Estimate for Precision BioSciences, Inc. (NASDAQ:DTIL) Issued By HC Wainwright
Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 earnings estimates for shares of Precision BioSciences in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.77) for the quarter, up from their prior estimate of ($1.26). HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. HC Wainwright also issued estimates for Precision BioSciences’ Q3 2024 earnings at ($0.79) EPS, Q4 2024 earnings at ($0.43) EPS, Q1 2025 earnings at ($0.39) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.06) EPS. Precision BioSciences (NASDAQ:DTIL – Get Free Report) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($3.35) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.00 by ($6.35). The firm had revenue of $7.04 million during the quarter, compared to the consensus estimate of $28.50 million. Precision BioSciences had a negative return on equity of 131.69% and a negative net margin of 48.10%. Separately, Guggenheim assumed coverage on shares of Precision BioSciences in a research note on Tuesday, April 30th. They set a “buy” rating and a $19.00 price target for the company. Read Our Latest Report on DTIL Precision BioSciences Price Performance Shares of NASDAQ DTIL opened at $12.40 on Monday. The company has a market cap of $85.93 million, a P/E ratio of -1.66 and a beta of 1.62. Precision BioSciences has a 1 year low of $8.25 and a 1 year high of $27.02. The firm has a 50-day simple moving average of $11.96 and a two-hundred day simple moving average of $11.98. Institutional Trading of Precision BioSciences A number of institutional investors and hedge funds have recently modified their holdings of DTIL. Curi Wealth Management LLC increased its stake in shares of Precision BioSciences by 42.0% during the third quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock worth $116,000 after purchasing an additional 100,530 shares in the last quarter. Tejara Capital Ltd increased its stake in shares of Precision BioSciences by 100.7% during the third quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock worth $136,000 after purchasing an additional 200,000 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Precision BioSciences by 8.3% during the third quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock worth $1,073,000 after purchasing an additional 242,425 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of Precision BioSciences during the first quarter worth about $7,739,000. Hedge funds and other institutional investors own 37.99% of the company’s stock. Precision BioSciences Company Profile (Get Free Report) Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. See Also Five stocks we like better than Precision BioSciences Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time MarketBeat Week in Review – 5/13 – 5/17 Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed Take-Two Interactive Software Offers 2nd Chance for Investors The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
